Phio Pharmaceuticals (PHIO) Consolidated Net Income (2011 - 2026)

Phio Pharmaceuticals (PHIO) has 16 years of Consolidated Net Income data on file, last reported at -$4.0 million in Q1 2026.

• Quarterly Consolidated Net Income fell 146.98% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 28.57% YoY) and the FY2024 annual result came in at -$7.7 million, up 42.4% from the prior year.
• Consolidated Net Income slipped to -$4.0 million in Q1 2026, from -$2.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$1.5 million in Q3 2024 to a low of -$4.0 million in Q1 2026.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2024 — Consolidated Net Income soared 45.78% — and 2026, when it plunged 146.98%.
• Tracing PHIO's Consolidated Net Income over 5 years: stood at -$2.8 million in 2022, then surged by 34.66% to -$1.8 million in 2023, then gained by 5.09% to -$1.7 million in 2024, then tumbled by 39.56% to -$2.4 million in 2025, then sank by 67.47% to -$4.0 million in 2026.
• The last three Consolidated Net Income figures came in at -$4.0 million (Q1 2026), -$2.4 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.